Cancer Profiling and Pathways: Technologies and Global Markets



 

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cancer Profiling and Pathways: Technologies and Global Markets

http://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.html

STUDY GOALS AND OBJECTIVES

This BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and pathways. This report analyzes in detail the cancer profiling and tools markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer profiling methods, strengths, weaknesses, opportunities and challenges, major issues involved in the research and development (R&D) of more effective cancer profiling techniques, and new cancer therapeutics in development and in clinical trials.


REASONS FOR DOING THE STUDY

Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Life Technologies, Agilent and Affymetrix, respectively, are maintaining their leads in the quantitative real-time PCR and microarray market segments. Understanding the multivariate nature of cancer and drug response also depends on molecular profiling at epigenetic, genetic and protein levels. A major challenge is to develop an understanding of this multivariate dysregulation, with respect both to how it arises from diverse genetic mutations and to how it may be ameliorated by prospective treatments. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market.

SCOPE OF REPORT

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.
Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.
The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.
This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also looks into recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.


INTENDED AUDIENCE

This report is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies and segments, important trends in technology development, next-generation technologies, major opportunities and market shares of key players and innovative drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. As market needs change with progress, the value of the information provided from microarrays, sequencing and qRT-PCR has become more interesting for markets outside of basic life-science research. In oncology-expression pattern profiling, comparing expression in normal and cancer tissues shows an unexpected greater reliability in classifying cancer types than the signatures of protein-coding genes. Researchers have also successfully classified poorly differentiated tumors using expression profiles. Along with their diagnostic potential, cancer-profiling techniques have also reportedly proven to be of prognostic value to predict survival among cancer patients and poor responsiveness to adjuvant chemotherapy and other drugs.


METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news, and developments and through access to paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of cancer, incidence, development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, current product growth, etc. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on prostate cancer assay development and previously marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific-related journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.


INFORMATION SOURCES

Many companies within the industry were contacted to obtain data for this study. Included were manufacturers and end users of products, which included pharmaceutical and biotechnical industries, research institutes, etc. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.


REPORT HIGHLIGHTS

The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.

This report provides:
• An overview of the global market for cancer profiling and biomarker studies
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Discussion of products in this market, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market
• Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
• Identifications of important cancer profiling techniques, market share by type of products on the market and market share by company, as well as types of cancers and biomarkers
• Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products
• Comprehensive company profiles of key players in the market.
TABLE OF CONTENTS


CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY 4
INFORMATION SOURCES 4
ABOUT THE AUTHOR 4
RELATED BCC RESEARCH REPORTS 5
BCC RESEARCH ONLINE SERVICES 5
DISCLAIMER 5

CHAPTER 2 SUMMARY 7

CANCER PROFILING AND PATHWAYS 7
SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH
2018 ($ MILLIONS) 9
SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 ($
MILLIONS) 9


CHAPTER 3 OVERVIEW 11

CANCER PROFILING 11
BIOMARKERS 11
GUIDELINES 11
SCREENING TESTS 12
EARLY DETECTION AND DIAGNOSIS OF CANCER 12
PATHWAY PROFILING 13
LINKING CANCER DISEASE THROUGH PATHWAY PROFILING 13
MOLECULAR PROFILING 13
HISTORICAL FACTS 14
MOLECULAR PROFILES 14
ONCOTYPE DX 15
CANCER PROFILING 15
CHALLENGES 16
PRIMARY OBJECTIVES OF THE MINDACT TRIAL 18
Lung Cancer 19
Challenges 19
CLINICAL UTILITY OF MOLECULAR PROFILING 20
CARIS LIFE SCIENCES 21
Head and Neck Cancer Data 22
Pathological Classification 22
MOLECULAR PROFILING APPROACHES 23
TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER 24
CANCER PROFILING: FUTURE GOALS 25


CHAPTER 4 CURRENT PROFILING TECHNIQUES 27

GENOMICS 27
TABLE 2 GENOMICS: TECHNOLOGIES 27
TABLE 3 THE APPLICATIONS MARKET 28
TABLE 4 THE SEGMENT TYPES 28
GENOMIC PROFILING 28
TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING 30
TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 32
FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 32
Challenges and Market Trends 32
MICROARRAYS 33
TABLE 7 COMMONLY USED DNA MICROARRAYS 34
Oligonucleotide Microarrays 34
Spotted Microarrays 35
Microarrays Fabrication 35
MICROARRAYS: LIMITATIONS 36
MICROARRAYS AND APPLICATIONS 37
COMPARATIVE GENOMIC HYBRIDIZATION (CGH) 37
Method 38
ARRAY COMPARATIVE GENOME HYBRIDIZATION 38
Applications of Array-CGH 40
CGH AND CANCER 41
Array CGH and Neuroblastoma 41
KEY COMPANIES 42
TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES 42
KEY PLAYERS 42
Genomic Profiling - Array Labeling and Genotyping 44
MICROARRAYS TO CLINICAL PROBLEMS 45
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) 45
TABLE 9 KEY COMPANIES 46
MULTI-COLOR FISH 46
Spectral Karyotyping 46
COMPANIES 47
DNA SEQUENCING 47
EMERGING DNA SEQUENCING TECHNOLOGIES 48
Fluorescent in situ Sequencing (FISSEQ) 48
Pyrosequencing 48
Massively Parallel Signature Sequencing (MPSS) 48
Single-Molecule Sequencing 49
Bacterial Artificial Chromosome (BAC)-end Sequencing 49
HIGH-THROUGHPUT SEQUENCING 49
In vitro Clonal Amplification 49
Parallelized Sequencing 50
Sequencing by Ligation 50
Microfluidic Sanger Sequencing 50
OTHER SEQUENCING TECHNOLOGIES 50
APPLICATIONS TO CANCER 51
SEQUENCING TECHNOLOGIES, MARKET AND THEIR APPLICATIONS 52
NEXT-GEN SEQUENCING SERVICES 52
TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES 53
Key Companies 53
TABLE 11 NEXT-GEN SEQUENCING COMPANIES 53
THE NEXT NEXT-GENERATION COMPANIES 54
Roche 454 Pyrosequencing 54
Illumina NGS Sequencing 54
Ion Torrent NGS Sequencing 55
Applications of NGS Sequencing 55
LATEST DEVELOPMENTS 55
Complete Genomics 56
Nanopore Sequencing 56
Genia 56
GENOME SEQUENCING 57
PATENTS AND SEQUENCING 58
TABLE 12 SEQUENCING PATENTS AWARDED 58
SUMMARY 59
NEXT-GENERATION SEQUENCING TECHNOLOGIES 59
NEXT-GENERATION SEQUENCING: FUTURE 60
GENOMICS AND CANCER-SOME EXAMPLES 60
TABLE 13 MUTATIONS IDENTIFIED IN CANCER 61
MUTATIONS PREDICTING RESISTANCE TO TARGETED THERAPIES 62
SEQUENCING AND THE CLINIC 62
TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES 63
TRANSCRIPTOMIC PROFILING 65
TABLE 15 TRANCRIPTOMIC TECHNIQUES 65
MICROARRAY-BASED GENE EXPRESSION PROFILING 66
Serial Analysis of Gene Expression (SAGE) 68
mRNA 68
Data Analysis and Design 69
TILING ARRAYS 70
QRT-PCR 71
APPLICATIONS TO CANCER 71
EMERGING MICROARRAY TECHNOLOGIES 72
MICROARRAY PATENTS 72
FUTURE 73


CHAPTER 5 EPIGENOMIC PROFILING 75

OVERVIEW AND INTRODUCTION TO THE EPIGENETICS LANDSCAPE 75
APPLICATIONS TO CANCER 75
DNA METHYLATION 76
Covalent Histone Modifications 77
Histone Modifications in Cancer 80
MICRORNA 81
MicroRNA Technologies: Impact on Diagnostics and Therapeutics 82
TABLE 16 MIRNA AND SIRNA-A COMPARISON 83
MicroRNA Expression 83
EPIGENETIC CHANGES AND CANCER STEM CELLS 84
EPIGENETIC THERAPY OF CANCER 85
TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA 87
TABLE 18 HDAC DRUGS 88
LEADING EPIGENETIC COMPANIES 89
TABLE 19 SELECTED EPIGENETIC COMPANIES 90
EPIGENETICS AND MICRORNA PROFILING-FINDING PATHWAYS TO
TREATMENT 91
TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES 92
Human Cancer and Epigenetic Regulation of miRNAs 93
TABLE 21 MICRORNA EXPRESSION IN CANCER 94
TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY 95
MICRORNAS AND THERAPEUTIC APPLICATIONS IN CANCER 95
POLYMORPHISMS IN MICRORNAS ASSOCIATED WITH CANCER RISK 97
MICRORNAS AS PROGNOSTIC AND THERAPEUTIC BIOMARKERS 98
microRNA as Therapeutic Targets 98
Computational Methods for Analysis of Cellular Functions and
Pathways 99
TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN
COLON CANCER 101
ANTI-CANCER DRUGS AND MICRORNA TARGETS 102
TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN
PANCREATIC CANCER 103
CASE STUDY: EPIGENETIC SILENCING OF THE INTRONIC MICRORNA
MIR-342 IN COLORECTAL CANCER 106
TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL
COLORECTAL TISSUE 107
TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND
EARLY-STAGE COLORECTAL CANCER (STAGES I AND II) 108
TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS
LATE-STAGE (III AND IV) DISEASE 109
TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS 109
DIAGNOSTIC AND THERAPEUTIC MICRORNA STRATEGIES IN CANCER 110
TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS:
POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT 113
THERAPEUTIC POTENTIAL 114
TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN
CARCINOMA 116
Challenges and Future 118
THERAPEUTIC STRATEGIES 118
Implications for Cancer 120
MICRORNAS IN DISEASE DIAGNOSTICS 120
CIRCULATING MICRORNAS 120
MICRORNA PROFILING METHODS 121
CLINICAL MICRORNA DIAGNOSTICS 121
Nucleotide Polymorphism in Diagnostics 122
MICRORNAS IN THERAPEUTICS 122
TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS 123
Miravirsen (Santaris Pharma) 124
Regulus Therapeutics 124
TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER 125
Mirna Therapeutics 125
miRagen Therapeutics 126
MICRORNA PATENTS AND OUTLOOK 127
Regulus, Alnylam, and Isis Announce U.S. Allowance of Tuschl III
Patent Application Covering miR-21 127
TABLE 33 MICRORNA PATENTS 128
FUTURE 129
TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 130
FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 130
TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS 131
METHYLATION MARKERS 132
DNA METHYLATION, AN EPIGENETIC PROCESS 132
CURRENT METHODS AND PRODUCTS 133
Cancer-Specific Methylation Biomarkers 135
CLINICAL IMPLICATIONS 136
TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION
PROFILES AND CELL SURFACE HORMONAL EXPRESSION 137
Clinical Testing 138
Blood-Based Tests 139
FUTURE DIRECTIONS 139
TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES 140
EPIGENETIC DIAGNOSTIC DEVELOPMENT 141
TABLE 38 SELECTED METHYLATION TESTS FOR CANCER 142
EPIGENETIC DRUGS 142
HDAC INHIBITORS 143
Novel HDIs on Trial 144
Celleron 145
Acetylon Pharmaceuticals 145
Syndax 146
TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018
($ MILLIONS) 147
FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 147
EPIGENETIC THERAPEUTIC DEVELOPMENT 147
TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL
TRIALS 148
Latest Developments 148
September 11, 2013 148
August 27, 2013 149
December 18, 2012 149
September 13, 2012 149
Pracinostat 149
MEI Pharma 150
S*BIO 150
Panobinostat 150
KEY PLAYERS 151
CellCentric 151
Epigenomics 151
Constellation Pharmaceuticals 152
Epizyme 152
Abbott 152
Veridex 153
OncoMethylome Sciences 153
TABLE 41 METHYLATION MARKERS IN DEVELOPMENT 154
Quest Diagnostics 154
TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS 155
Orion Genomics 155
Zymo Research 157
BioChain 157
EpigenDx 157
Rubicon Genomics 158
SeqWright 158
Qiagen 159
TABLE 43 METHYLATION MARKERS/TESTS-PATENTS 160
EXACT Sciences Corporation 160
Activemotif 161
Clinical Implications 163
OncoMethylome Sciences-GST-Pi/APC Methylation Test for Detection
of Prostate Cancer 163
MDxHealth 165
Summary 165


CHAPTER 6 PROTEOMICS 167

PROTEOMICS AND PROTEIN PROFILING 167
PROTEOMICS PROTEIN PROFILING APPROACHES 168
TECHNIQUES 170
TABLE 44 BIOMARKER INDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS
(2-DE) 170
TABLE 45 BIOMARKER INDENTIFIED USING MASS SPECTROSCOPY (MS) 171
APPLICATIONS OF PROTEOMIC TECHNIQUES IN CANCER RESEARCH 173
TECHNOLOGIES AND LIMITATIONS 174
PROTEOMICS AND INITIATIVES 175
APPLICATIONS TO CANCER 176
PROTEOMICS IN THE TREATMENT OF CANCER 178
CLINICAL APPLICATIONS OF PROTEOMICS 180
Lung Cancer 180
Ovarian Cancer 181
Prostate Cancer 183
Breast Cancer 184
PROTEOMIC APPROACHES IN THERAPEUTIC TARGETS 185
KEY PLAYERS 187
Kreatech Biotechnology 187
Thermo Fisher Scientific 187
GE Healthcare 187
ProteinOne 188
Waters 188
PerkinElmer 189
Protneteomix 189
Whatman 189
Arrayit Corporation 190
Qiagen 190
TABLE 46 ANTIBODY ARRAY VENDORS 191
ANALYTICAL SOFTWARE 192
THERAPEUTIC AND DIAGNOSTIC COMPANIES 193
PROTEOMICS-BASED DIAGNOSTIC PRODUCTS 195
Myriad Genetics 195
NextGen Sciences 195
ProFACT Proteomics 195
Proteologics 196
Proteome Factory 196
ProteomTech 197
Pharmaceutical Candidates 197
Quattromed 198
Sense Proteomic Limited 198
SomaLogic 198
Structural Bioinformatics (SBI) 198
WITA Proteomics 199
Zyomyx 199
PROTEOMIC RESEARCH CENTERS 200
Stanford University: Molecular Therapeutics Program 200
Vanderbilt University-Mass Spectrometry Research Center (MSRC) 200
CLINICAL TRIAL USING PROTEOMICS TECHNOLOGIES FOR PERSONALIZED
MEDICINE 202
PROTEOMICS AND MEDICINE 203
PROTEOMICS MARKET 203
TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING,
THROUGH 2018 ($ MILLIONS) 203
FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING,
2012-2018 ($ MILLIONS) 204
Applied Proteomics 204


CHAPTER 7 GLYCOMICS 207

WHAT IS GLYCOMICS? 207
TECHNIQUES 207
ANALYTICAL HIGH-THROUGHPUT TECHNOLOGIES 209
EMERGENCE OF GLYCOARRAYS 209
GLYCOINFORMATICS 210
BIOMEDICAL APPLICATIONS 210
GLYCOMICS'S RELATIONSHIP WITH OTHER "OMICS" TECHNOLOGIES 211
GLYCOMICS FOR BIOMARKER DISCOVERY 212
TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES 212
CANCER AND GLYCOMICS 213
Glycomics-Biomarkers for Ovarian Cancer 213
TABLE 49 CLINICAL TRIALS AND GLYCOMICS 214
GLYCOMICS AND PATENTS 215
Carbohydrate Encapsulated Nanoparticles 215
Glycosylated Specificity Exchangers (Tripep) 215
Glycosylated Specificity Exchangers (Tripep) 215
Tripep AB/ChronTech Pharma AB 215
TABLE 50 GLYCOMICS PATENTS 216
Serum Marker for Measuring Liver Fibrosis 216
Recent Advances 217

CHAPTER 8 METABOLOMICS 219

WHAT IS METABOLOMICS? 219
METABOLOME 219
Techniques 220
Detection Methods 221
METABOLOMICS AND DRUG DISCOVERY 222
BIOMARKER IDENTIFICATION 222


CHAPTER 9 BIOINFORMATICS, DATABASES AND PATHWAY ANALYSIS 225

MICROARRAY DATABASE 225
TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY
DATABASES 226


CHAPTER 10 CANCER PROFILING AND CLINICAL DEVELOPMENT 231

NODALITY 231
ROSETTA CANCER TESTING SERVICES 232
IRIS BIOTECHNOLOGIES 232
IN BREAST CANCER-THREE PERSPECTIVES ILLUSTRATING CURRENT
CHALLENGES IN PERSONALIZED MEDICINE 233
BIOMARKERS 235
DIAGNOSTIC TESTS IN DEVELOPMENT 235
TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT 235
APPROVED TESTS 236
Affymetrix 236
Agendia 236
TABLE 53 APPROVED DIAGNOSTIC TESTS 237
GENOMIC ASSAYS 238
TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET 239
GENOMIC HEALTH BUSINESS PROGRESS 239
TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 ($ MILLIONS) 239
MammaPrint Assay 239
CANCER AND BIOMARKERS 240
TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY 242
TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER 244
FUTURE DIRECTIONS 248
TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN
COLORECTAL CANCER 249


CHAPTER 11 MARKET 252

GLOBAL DNA DIAGNOSTICS MARKET 252
TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 ($
MILLIONS) 252
FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 ($ MILLIONS) 252
THE CANCER DIAGNOSTICS MARKET 253
CANCER DIAGNOSTIC TESTS 253
THE CANCER/TUMOR PROFILING MARKET 253
TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES 254
TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018
($ MILLIONS) 254
TABLE 62 CANCER PROFILING MARKET: APPLICATIONS 255
TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES 255
PERSONALIZED MEDICINE 255
CANCER BIOMARKER TESTING MARKET 256
TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 257
FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 257
TABLE 65 THE KEY PLAYERS 258
TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 258
FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018
($ MILLIONS) 258
CANCER BIOMARKER TESTS 259
CANCER DISEASE MANAGEMENT 259
GENOMICS MARKET 260
Trends 261
TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 ($
MILLIONS) 261
FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 261
SNP GENOTYPING AND ANALYSIS MARKET 262
TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 262
FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 263
MICROARRAY MARKET 263
TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 264
FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 264
TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%) 265
TABLE 71 MICROARRAY MARKETS 266
Key Microarray Companies 266
Microarray Use 267
TABLE 72 MICROARRAYS: MODALITIES 267
Global Microarray Market 268
TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 268
FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 ($ MILLIONS) 268
TABLE 74 MICROARRAY MARKET SHARE, 2012 (%) 269
BIOCHIP/LAB-ON-A-CHIP (LOAC) MARKET 269
TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 ($
MILLIONS) 270
FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 ($ MILLIONS) 270
DIAGNOSTIC MICROARRAYS 270
TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 271
FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 271
TABLE 77 SOME COMMERCIALLY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED
ON MICROARRAY TECHNOLOGY 272
In Situ Hybridization Diagnostic Arrays 272
TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 272
FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 272
Microarray Market Growth 273
TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS 274
DNA Microarrays 275
FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 ($ MILLIONS) 276
MARKET DYNAMICS 276
KEY PLAYERS 277
Affymetrix 277
Recent Developments 277
TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (THOUSANDS) 278
Agilent Technologies 278
TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 ($ MILLIONS) 278
Product Sales 279
TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%) 279
Strategic Alliances and Acquisitions 280
Historical Trends and Future 281
TABLE 84 MICROARRAY PRODUCTS 281
Illumina 281
Pacific Biosciences 282
Arrayit Corporation 282
TABLE 85 ARRAYIT PATENTS 283
Arrayit Products 283
TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 ($) 284
Arrayit's Future 285
Roche 285
PerkinElmer 286
Boreal Genomics 286
DNA SEQUENCING MARKET 286
First-Generation DNA Sequencing 286
NEXT-GENERATION SEQUENCING SYSTEMS 287
A NEW GENERATION OF DNA SEQUENCING 287
DNA SEQUENCING AND PERSONALIZED MEDICINE 288
TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 289
FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 289
TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS 290
HISTORY 290
TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS,
2011-2013 292
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY 293
TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET
SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 294
TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR
MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 295
NEXT-GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY 296
TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT
INDUSTRY COMPANY PLATFORM METHOD 296
TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE
COMPETITORS 298
Developments 298
Roche 299
Illumina 299
TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 300
TABLE 95 ILLUMINA NEW DEVELOPMENTS 300
TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015
($ MILLIONS) 301
TABLE 97 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
FIGURE 17 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS 303
MARKET SHARE 303
Oxford Nanopore 304
Life Technologies 304
TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
PCR MARKET 307
TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 307
FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 307
TABLE 101 KEY PCR COMPANIES 308
TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS
MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 309
FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS
MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 309
REAL-TIME PCR MARKET 309
TABLE 103 REAL-TIME (QRTPCR) PCR SELECTED COMPANIES 310
TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 ($ MILLIONS) 311
FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 ($ MILLIONS) 311
EPIGENETICS AND MARKET 312
TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 313
FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 314
TABLE 106 EPIGENETIC MARKET: KEY PLAYERS 314
TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES 315
EPIGENETIC THERAPEUTICS 316
TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALLY AVAILABLE 316
FUTURE: EPIGENETIC THERAPIES 317
TABLE 109 EPIGENETICS AND SELECTED COMPANIES 318
EPIGENETICS AND DIAGNOSTIC TESTS 319
TABLE 110 EPIGENETIC DIAGNOSTIC TESTS 319
MIRNA MARKET 319
TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 320
FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 321
TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%) 322
EPIGENETICS AND CANCER MARKET AND FUTURE GROWTH 322
TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS 323
CURRENT USE OF PROTEOMICS IN THE PHARMA INDUSTRY 323
TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018
($ MILLIONS) 323
FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 ($
MILLIONS) 323
TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 324
FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 324
PROTEIN MICROARRAYS AND TRENDS 325
THE METABOLOMICS MARKET 326
FUTURE 328
CONCLUSION 329
TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO
DEVELOP COMPANION DIAGNOSTICS 329


CHAPTER 12 COMPANY PROFILES 332

KEY PLAYERS 332
ABBOTT LABORATORIES 332
AFFYMETRIX 332
AGENDIA 333
AGILENT TECHNOLOGIES 334
ARRAYIT 334
ASTRAZENECA PLC. 335
ASURAGEN, INC. 335
BOREAL GENOMICS 336
CARIS LIFE SCIENCES 336
CLARINET 336
DAKO 337
EISAI INC. (HEADQUARTERS) 337
ENDOTIS PHARMA 338
EPPENDORF BIOCHIP SYSTEMS 338
EXIQON, INC 338
GENOMIC HEALTH 339
GLAXOSMITHKLINE 339
GLYCOMINDS LIMITED 339
GP BIOSCIENCES 340
IKARYOS DIAGNOSTICS 340
ILLUMINA 341
LIFE TECHNOLOGIES 341
LIPOMICS TECHNOLOGIES 341
MERCK 342
METABOLON 342
MIRAGEN THERAPEUTICS 342
MIRNA THERAPEUTICS INC. 343
OXFORD GENE TECHNOLOGY 343
Oxford Nanopore Technologies 343
PACIFIC BIOSCIENCES 344
PERKINELMER 344
PFIZER 345
PROTEOME SCIENCES 345
RAYBIOTECH 345
REGULUS THERAPEUTICS 346
ROCHE 346
RUBICON GENOMICS 346
TABLE 117 MICROARRAY COMPANIES 347


CHAPTER 13 CANCER PROFILING: PATENT LANDSCAPE AND LATEST DEVELOPMENTS 350

TABLE 118 PATENT APPLICATIONS IN MICROARRAYS 351
MIRNA THERAPEUTICS 354
TROVAGENE 355
TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES 356
COLUMBIA UNIVERSITY SUES ILLUMINA OVER DNA SEQUENCING PATENTS 357
MAJOR CANCER GENOTYPING STUDY LOGS 5,000TH TUMOR PROFILE 358
Developing a Cancer-Specific Microarray 359
Oxford Nanopore Announces $64 Million Fundraising 359
Silicon Peptide Chips Could Transform Diagnostics 359
Agilent Technologies Introduces HaloPlex Exome Kits and SureCall
Software 360
PROTEOME SCIENCES 361
CONCLUSIONS 362


CHAPTER 14 REFERENCES 364

CHAPTER 15 CITED REFERENCES 368

CITED REFERENCES 368



LIST OF TABLES

SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2018
($ MILLIONS) 9
TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER 24
TABLE 2 GENOMICS: TECHNOLOGIES 27
TABLE 3 THE APPLICATIONS MARKET 28
TABLE 4 THE SEGMENT TYPES 28
TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING 30
TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 ($ MILLIONS) 32
TABLE 7 COMMONLY USED DNA MICROARRAYS 34
TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES 42
TABLE 9 KEY COMPANIES 46
TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES 53
TABLE 11 NEXT-GEN SEQUENCING COMPANIES 53
TABLE 12 SEQUENCING PATENTS AWARDED 58
TABLE 13 MUTATIONS IDENTIFIED IN CANCER 61
TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES 63
TABLE 15 TRANCRIPTOMIC TECHNIQUES 65
TABLE 16 MIRNA AND SIRNA-A COMPARISON 83
TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA 87
TABLE 18 HDAC DRUGS 88
TABLE 19 SELECTED EPIGENETIC COMPANIES 90
TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES 92
TABLE 21 MICRORNA EXPRESSION IN CANCER 94
TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY 95
TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN
COLON CANCER 101
TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN
PANCREATIC CANCER 103
TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL
COLORECTAL TISSUE 107
TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND
EARLY-STAGE COLORECTAL CANCER (STAGES I AND II) 108
TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE
(III AND IV) DISEASE 109
TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS 109
TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS:
POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT 113
TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA 116
TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS 123
TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER 125
TABLE 33 MICRORNA PATENTS 128
TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 130
TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS 131
TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION
PROFILES AND CELL SURFACE HORMONAL EXPRESSION 137
TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES 140
TABLE 38 SELECTED METHYLATION TESTS FOR CANCER 142
TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018
($ MILLIONS) 147
TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL
TRIALS 148
TABLE 41 METHYLATION MARKERS IN DEVELOPMENT 154
TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS 155
TABLE 43 METHYLATION MARKERS/TESTS-PATENTS 160
TABLE 44 BIOMARKER INDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS
(2-DE) 170
TABLE 45 BIOMARKER INDENTIFIED USING MASS SPECTROSCOPY (MS) 171
TABLE 46 ANTIBODY ARRAY VENDORS 191
TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING,
THROUGH 2018 ($ MILLIONS) 203
TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES 212
TABLE 49 CLINICAL TRIALS AND GLYCOMICS 214
TABLE 50 GLYCOMICS PATENTS 216
TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY DATABASES 226
TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT 235
TABLE 53 APPROVED DIAGNOSTIC TESTS 237
TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET 239
TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 ($ MILLIONS) 239
TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY 242
TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER 244
TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN
COLORECTAL CANCER 249
TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 ($
MILLIONS) 252
TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES 254
TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 254
TABLE 62 CANCER PROFILING MARKET: APPLICATIONS 255
TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES 255
TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 257
TABLE 65 THE KEY PLAYERS 258
TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 258
TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 ($
MILLIONS) 261
TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 262
TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 264
TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%) 265
TABLE 71 MICROARRAY MARKETS 266
TABLE 72 MICROARRAYS: MODALITIES 267
TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 268
TABLE 74 MICROARRAY MARKET SHARE, 2012 (%) 269
TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 270
TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 271
TABLE 77 SOME COMMERCIALLY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED
ON MICROARRAY TECHNOLOGY 272
TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 272
TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS 274
TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (THOUSANDS) 278
TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 ($ MILLIONS) 278
TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%) 279
TABLE 84 MICROARRAY PRODUCTS 281
TABLE 85 ARRAYIT PATENTS 283
TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 ($) 284
TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 289
TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS 290
TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS,
2011-2013 292
TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET
SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 294
TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR
MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%) 295
TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY
COMPANY PLATFORM METHOD 296
TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS 298
TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 ($ MILLIONS) 300
TABLE 95 ILLUMINA NEW DEVELOPMENTS 300
TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015
($ MILLIONS) 301
TABLE 97 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS 303
TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 307
TABLE 101 KEY PCR COMPANIES 308
TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS
MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 309
TABLE 103 REAL-TIME (QRTPCR) PCR SELECTED COMPANIES 310
TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 ($ MILLIONS) 311
TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 313
TABLE 106 EPIGENETIC MARKET: KEY PLAYERS 314
TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES 315
TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALLY AVAILABLE 316
TABLE 109 EPIGENETICS AND SELECTED COMPANIES 318
TABLE 110 EPIGENETIC DIAGNOSTIC TESTS 319
TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 320
TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%) 322
TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS 323
TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018
($ MILLIONS) 323
TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 324
TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO
DEVELOP COMPANION DIAGNOSTICS 329
TABLE 117 MICROARRAY COMPANIES 347
TABLE 118 PATENT APPLICATIONS IN MICROARRAYS 351
TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES 356



LIST OF FIGURES

SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 ($
MILLIONS) 9
FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 32
FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 130
FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 147
FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING,
2012-2018 ($ MILLIONS) 204
FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 ($ MILLIONS) 252
FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 257
FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 258
FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 ($ MILLIONS) 261
FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 263
FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 264
FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 ($ MILLIONS) 268
FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 ($ MILLIONS) 270
FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 271
FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 272
FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 ($ MILLIONS) 276
FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 289
FIGURE 17 ILLUMINA-REVENUE, 2008-2010 ($ MILLIONS) 302
FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 ($ MILLIONS) 305
FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST,
2012-2018 ($ MILLIONS) 307
FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS
MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 309
FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 ($ MILLIONS) 311
FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 314
FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 321
FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 ($
MILLIONS) 323
FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 324



Read the full report:
Cancer Profiling and Pathways: Technologies and Global Markets

http://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer



RELATED LINKS
http://www.reportbuyer.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.